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ANTI-CANCER DRUGS
The mitochondrial paradox
A structural motif that is found in two cancer drugs may be responsible
for their ability to tackle cancers and for the side-effects caused by the
drugs.
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O
rganelles called mitochondria are
often referred to as the powerhouse
of a cell because they make the mole-
cules of ATP that the cell uses as a source of
energy. The toxic side-effects of some medicines
are caused by the drug inadvertently disrupting
the workings of mitochondria (Nadanaciva and
Will, 2011). The heart is particularly susceptible
to such side-effects because cardiac cells contain
large numbers of mitochondria to meet the
energy demands of heart tissue (Park et al.,
2014; Varga et al., 2015). Understanding how
this toxicity arises is important so it can be
avoided when designing and developing new
treatments. However, it can be diffucult to
determine which part of the drug causes these
toxic side-effects.
Now, in eLife, Anne Willis (University of Cam-
bridge) and colleagues – including Zoe¨ Stephen-
son as first author – report details of a chemical
structure in the anti-cancer drug mubritinib,
which inhibits the mitochondria of cardiac cells
and causes an unintended rise in toxicity
(Stephenson et al., 2020). Previous work had
shown that mubritinib disrupts the phosphoryla-
tion of a protein called HER2 that is known to
promote the growth of cancer cells
(Nagasawa et al., 2006). However, during tests,
Stephenson et al. found that increasing the con-
centration of mubritinib did not hinder this pro-
tein to the same degree as a drug called
lapatinib, which is known to work by inhibiting
HER2. This suggested that mubritinib does not
directly inhibit HER2 and that another mecha-
nism is likely to be responsible for its anti-cancer
effects.
As mubritinib is known to affect pathways
that are linked to cellular energy, the researchers
– who are based at University of Cambridge and
the University of Nottingham – decided to inves-
tigate how this drug impacted the production of
ATP in cardiac cells cultured in two media: glu-
cose and galactose. Cells cultured in galactose
rely more heavily on mitochondria for ATP pro-
duction than cells cultured in glucose, so are
more susceptible to compounds that target this
organelle (Marroquin et al., 2007). Stephenson
et al. found that, following drug treatment, the
cells in galactose produced less ATP and had a
lower frequency of beating than the cells in glu-
cose. This suggests that mubritinib impairs the
activity of the electron transport chain which
drives the synthesis of ATP (Figure 1). Further
analysis revealed that mubritinib inhibits a partic-
ular structure within this chain called ’complex I’.
Next, Stephenson et al. investigated a library
of compounds which have a similar structure to
mubritinib to identify the ’toxicophore’ – the
region of the drug that is causing the side-
effects. This revealed that a region called the
heterocyclic 1,3 nitrogen motif was responsible
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for inhibiting complex I and reducing the pro-
duction of ATP (Figure 1).
The researchers then investigated the effects
of an anti-cancer drug called carboxyamidotria-
zole that contains the same toxicophore struc-
ture. This drug is thought to block the progress
of cancer by inhibiting specific ion channels that
transport calcium ions into the cell (Singh et al.,
2017). However, Stephenson et al. found that
carboxyamidotriazole did not significantly bind
to calcium channels. Instead, they discovered
that the drug reduced the production of ATP in
galactose media and decreased the amount of
oxygen taken up by cardiac cells.
Finally, to identify whether the heterocyclic
1,3 nitrogen motif was responsible for the anti-
cancer effects of both drugs, Stephenson et al.
measured the growth and death rate of cancer
cells following treatment. Cell lines representing
five different cancer types were treated with
mubritinib, carboxyamidotriazole, or structurally
similar compounds which lacked the toxico-
phore. In each cell line they tested, the presence
of the toxicophore resulted in increased levels of
Figure 1. A structural motif in two anti-cancer drugs disrupts the production of ATP. Mitochondria (top left)
make the ATP molecules that provide cells with energy. Chains of protein complexes called electron transporters
(purple; labelled I, II, III, IV and V) are embedded in the inner membrane of mitochondria. The first complex in this
chain (complex I) converts NADH to NAD+ by removing an electron (middle panel), which then gets shuttled
between the different complexes in the chain. This allows the complexes to actively transport protons (H+) into the
space between the inner and outer membrane of the mitochondrion. The diffusion of these protons back across
the inner membrane (downward black arrow) drives the enzyme that synthesizes ATP molecules. Two anti-cancer
drugs, mubritinib and carboxyamidotriazole, contain a motif (top right) which inhibits complex I and consequently
disrupts the production of ATP. Stephenson et al. found that inhibiting complex I in cancer cells led to reduced
growth and increased death (bottom left), whereas inhibiting complex I in cardiac cells caused the cells to beat
less frequently due to the reduction in ATP (bottom right).
Image credit: Sophie Penman.
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cell death and reduced rates of cell growth (Fig-
ure 1). This suggests that the toxicophore in
these two drugs is also partially responsible for
their anti-cancer effects.
These findings provide evidence of a chemi-
cal motif which increases the toxicity of cardiac
cells by inadvertently targeting mitochondria.
The identification of this motif could help design
safer and more effective anti-cancer treatments.
Furthermore, the method used in this study
could be used to identify other chemical motifs
which specifically disrupt the activity of mito-
chondria. Future research should test a larger
collection of compounds containing this toxico-
phore to confirm whether the loss in mitochon-
drial activity is linked to adverse side effects.
Furthermore, it is important to assess whether
these effects only cause toxicity in the heart or
whether other organs, such as the liver and kid-
ney, may also be susceptible.
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